Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.24.2.u1
Commitments and Contingencies (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 19, 2022
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
investor
Nov. 15, 2022
May 01, 2021
option
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Renewal options | option               4
Renewal period (in years)             1 year 1 year
Agreement term (in days)               90 days
General and administration   $ 7,212 $ 9,937 $ 14,805 $ 18,235      
Linebacker License Agreements                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Upfront license fee $ 50              
License agreement term (in days) 10 days              
License or royalty net revenue percentage 3.00%              
Royalty expense $ 250              
Linebacker License Agreements | Phase 3                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Additional payment of fee 900              
Linebacker License Agreements | New Drug Application                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Additional payment of fee $ 1,000              
Equivir License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of sites | investor           8    
General and administration   0 100 100 200      
BE-Smart License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
General and administration   $ 0 $ 200 $ 100 $ 300